Response Evaluation Criteria in Solid Tumors (RECIST) is used to assess patient response to anticancer therapy (1).
radiologists often fail to report tumor metrics,
save measurements in a picture archiving and communications system (PACS),
or compare lesions consistently across serial exams when using conventional narrative reporting (Figure 1).
We present a structured reporting system,
which captures a radiologist’s measurements and key images in...
Methods and Materials
We initially analyzed the serial radiology reports from ten patients with cancer to determine if radiologists conducted the following (Figure 2):
Reported tumor metrics
Saved the measurements in PACS
Correlated the same tumor metrics consistently across serial examinations
To address the need for more consistent tumor response assessment,
we created a structured reporting system,
which is also the subject of another EPOS poster,
“A ViSion for Global...
The analysis of conventional narrative radiology reports from baseline and immediate follow up examinations in a Phase I clinical trial at the MD Anderson Cancer Center revealed that radiologists reported measurements in 90% of cases,
saved measurements in the PACS in 20% of baseline and 50% of follow up studies,
and consistently correlated measurements of the same lesions in only 40% of patients.
The use of ViSion provided a means to record tumor measurements in 100% of cases by...
Conventional radiology reporting for tumor response assessment is often hindered by a radiologist’s failure to report tumor metrics,
save measurements in a PACS,
or compare the same lesions across serial examinations.
The ViSion structured reporting system provides a means for more consistent tumor response assessment.
Eisenhauer EA et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Sketching a new reality: what will the radiology report of the future look like? http://www.acr.org/News-Publications/News/News-Articles/2012/ACR-Bulletin/201203-Rad-Report-of-Future Accessed January 28,
Disclosure: David J.
is the founder,
and a major stockholder of VisionSR which has an option agreement with the University of Texas MD Anderson Cancer Center to license the ViSion technology for commercialization.
Department of Diagnostic Radiology,
UT MD Anderson Cancer Center,